Goldman Sachs on Hualan Biological (002007.SZ): H1 2026 Review: Revenue in Line, Net Profit Misses on Lower Gross Margin; Target Price Cut to RMB13; Neutral
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Goldman Sachs reaffirms Neutral on Hualan Biological (002007.SZ) and cuts its 12-month target price from RMB15 to RMB13 following the interim report released August 28. H1 2026 revenue of RMB1.567bn (-13% YoY) was broadly in line with GS estimates (RMB1.615bn), but gross margin of 46.2% fell well short of the expected 52.2%, dragging net profit down 26% to RMB383mn versus the RMB423mn forecast. Goldman argues the simultaneous decline in revenue and margin validates its call that China's blood products market is entering oversupply: demand-side volume-based procurement has lowered prices for some products while DRG/DIP payment reform further suppresses utilization, even as major manufacturers continue expanding plasma collection. The bank expects further industry consolidation and rising concentration. The RMB13 target price applies a 21x five-year exit P/E to 2026E EPS, a 10% five-year earnings CAGR and a 37.5% A/H premium; with the stock's one-year forward P/E in the second-highest quartile of its five-year history, Goldman views valuation as fair. Catalysts to watch include blood products supply-demand dynamics and flu vaccine uptake; risks span plasma station approvals, associates' results, deeper vaccine price cuts and stricter usage restrictions.